VIRX - Tenet reinstated buy at Goldman Sachs Adverum downgraded; in today's healthcare analyst action

Adverum Bio cut to market perform at SVB LeerinkAdverum Biotechnologies (ADVM) has gained ~3.8% in the premarket despite a downgrade by   SVB Leerink to market perform from outperform. The price target of $5.00 per share implies ~28.2% upside to the last close.The cancellation of a webcast on newly released data from the OPTIC trial ‘casts management in an evasive light and aligns with bear theses on likely timing delays in the wet AMD program,’ the analyst Mani Foroohar wrote.Last week, a safety event forced the company to unmask its INFINITY clinical trial evaluating ADVM-022 for the treatment of diabetic macular edema (DME).Tenet Healthcare reinstated buy at Goldman SachsGoldman Sachs has reinstated the coverage on Tenet Healthcare (THC) with a buy rating and the price target of $89.00 per share implies an upside of ~50.2% to the last close.Calling the guidance issued by the management for 2021 ‘conservative,’ the analyst Jamie Perse expects

For further details see:

Tenet reinstated buy at Goldman Sachs, Adverum downgraded; in today’s healthcare analyst action